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EDITORIALDisease-Associated Microbial Communities in Healthy Relatives:
A Bacteria-Filled Crystal Ball?he bacterial community within the gastrointestinalTtract has been the subject of a great deal of
investigation as well as a great deal of press. Numerous
studies have shown that inﬂammatory bowel disease
(IBD) is associated with an alteration in the ecological
system within our gut,1 and ﬁndings from mouse models
suggest that inﬂammation-associated microbiota trans-
planted from human IBD patients can contribute actively
to colitis.2 Still, it is not clear whether dysbiosis is either
necessary or sufﬁcient as an initiating event—especially
in human beings—or if in contrast only a microbiome that
already has been shaped by the inﬂammatory state is able
to contribute further to disease. If a dysbiosis is an
instigator, then in principle it should be possible to detect
this defect in otherwise healthy populations who are at
increased risk for disease, such as healthy relatives of IBD
patients.
In a new study published in this issue of Cellular and
Molecular Gastroenterology and Hepatology, Jacobs et al3
do exactly that. Performing a thorough analysis of fecal
microbial proﬁles from 36 IBD patients in remission (26
with Crohn’s disease and 10 with ulcerative colitis) and
54 healthy ﬁrst-degree relatives, they showed that it is
possible to identify an IBD-like intestinal microbiome in
at-risk healthy individuals who do not have clinically
detectable inﬂammation. In the study’s data set, in-
dividuals could be clustered into either a disease-
associated or a healthy microbial signature at both the
operational taxonomic unit (OTU) and metabolomic
levels. The IBD-associated microbial community type was
a reduced-diversity signature compared with the healthy
state, and included expansion of families such as
Enterobacteriaceae and Prevotellaceae. The metabotype
associated with IBD was enriched for taurine, tryptophan,
and altered bile acids and metabolites similar to those
shown previously to be altered with disease. Importantly,
given the small number of patients included here, the
investigators also used the much larger RISK data set of
early onset IBD4 to validate their diseased vs healthy
genomic grouping.
The key ﬁnding of their report was the observation
that the disease-linked OTU type and metabotype were
present in a substantial subset of clinically healthy
ﬁrst-degree relatives. Some of the healthy relatives with
an IBD-like microbial community had increased levels of
fecal calprotectin, suggesting that they may be on the road
to developing inﬂammation. Importantly, the majority of
this group did not have high calprotectin levels, which is
consistent with the idea that the microbial changes can
come before even subclinical inﬂammation. Together,Cellular and Molecular Gastroenterology and Hepatology 2016;2:710–7these observations raise the provocative possibility that,
at least in some individuals, the IBD-associated OTU type
represents a predisease or disease susceptibility state. At
the very least, they show that dysbiosis can occur in
at-risk individuals in the absence of obvious clinical
symptoms. This advance has the promise of clinical util-
ity—if necessary follow-up long-term studies show that
healthy family members with the IBD-type microbial
community are more likely to develop IBD, this signature
could be used to stratify relative risk. Furthermore,
although there have been substantive challenges with
attempts at therapeutic microbial alteration (eg, fecal
microbial transplant) in IBD, it may be the case that a
predisease/high-susceptibility gut ecology that has not
yet synergized with an ongoing inﬂammatory response
will be more amenable to treatment.
The metabolomic data presented in this study are
intriguing, although the direct causal links between the OTU
type and metabotype and the role of this metabotype in
instigating or prolonging disease are not yet known. For the
most part, the investigators found that the OTU and
metabolic types were well correlated. Interestingly, how-
ever, the taxonomy and metabotype were discordant in
approximately 20% of the individuals studied. The discor-
dant individuals were in both the healthy and IBD groups,
which does not rule out a contributory role but suggests, at
least at this level of analysis, that the metabotype described
in the report is not an essential driver of disease.
Going forward, prospective longitudinal studies in an
expanded and more diverse cohort will be essential to
determine whether the microbial signatures described by
Jacobs et al3 are indeed markers for a predisease state.
Furthermore, because evidence suggests that mucosa-
adherent microbes may correlate more tightly with the
disease state than fecal communities,5 it would be inter-
esting to see whether typing using these communities could
provide even more sensitive measures of susceptibility.
Overall, the presence of a distinct microbial community and
metabolomic signature in the absence of symptoms is an
important step toward understanding the sequence of IBD
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